Search 

Black Belt is a preclinical stage biotech company focused on the stress response in the tumour microenvironment. Black Belt targets cancers cells stress-associated survival mechanisms and reverts stress-induced immune cell dysfunction. We have built a diversified pipeline of first-in-class small molecule programmes as well as a proprietary target discovery and validation platform. The company is working with the acadmic KOLs in the stress response field. Black Belt has an experienced team of drug developers and was created as a spin-off from Tusk Therapeutics which was acquired by Roche in September 2018 for 655 million EUR.

Oxford based Biotech seeking partners to take forward our NCE assets in behavioural brain disease to complete IND enabling and move into clinic. We are open to licensing and funding/collaboration discussions. Orexin 1 antagonist in Addiction. Atypical DAT inhibitor in Fatigue (with potential in Narcolepsy).

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; color: #454545}

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood borne diseases. The company’s initial targets include Sepsis, Leukaemia and Malaria. Located in the new Imperial College Translation and Innovation Hub in White City, the company is preparing for first in man trials in 2019.

Microbiotica is founded on ground-breaking microbiome science from the Wellcome Sanger Institute, Cambridge UK. The company has unique capabilities to isolate all gut bacteria from any human and to identify gut bacterial signatures linked to patient phenotype from large clinical datasets with unprecedented precision. The business strategy is to use these to identify and progress best-in-class live bacterial therapeutics and to partner for drug-response biomarkers. The initial focus is in programs for IBD and Immuno-oncology, driven by best-in-class clinical datasets. The company has a $534m commercial partnership with Genentech, and clinical collaborations with Univ of Adelaide and Cambridge University Hospitals.

OxStem is a small molecule discovery company targeting innate regeneration and repair.

OxStem was founded by three eminent Oxford University professors with the goal of using small molecules to activate or re-program tissue-resident (endogenous) stem and progenitor cells. The founders were joined by thirteen world-leading Oxford scientists and physicians with respective expertise in OxStem's five programs: haematological malignancies, neurodegenerative diseases, retinal diseases, cardiovascular disease and diabetes.

Pneumagen is focusing on the treatment and prevention of infectious diseases and the treatment of cancer using a first-in-class, directed approach that targets glycans. Our platform technology, GlycoTarge™, is generating glycan targeted carbohydrate binding modules (mCBMs), as a new therapeutic modality for the universal treatment and prevention of respiratory tract infections (influenza and RSV) and also as direct therapies in oncology.